Englander Institute for Precision Medicine

Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.

TitleEctopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.
Publication TypeJournal Article
Year of Publication2016
AuthorsMeller S, VAN Ellen A, Gevensleben H, Bicker A, Hankeln T, Gorr TA, Sailer V, Dröge F, Schröck F, Bootz F, Schröck A, Perner S, Dietrich D, Kristiansen G
JournalAnticancer Res
Volume36
Issue12
Pagination6235-6241
Date Published2016 Dec
ISSN1791-7530
KeywordsAdolescent, Adult, Carcinoma, Squamous Cell, Child, Child, Preschool, Female, Head and Neck Neoplasms, Humans, Infant, Infant, Newborn, Male, Middle Aged, Myoglobin, Treatment Outcome, Young Adult
Abstract

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs).

PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed.

RESULTS: MB expression was found in 45.8% of HNSCC patients being significantly lower in normal adjacent tissue (NAT) compared to primary and recurrent tumours (p<0.001) and significantly associated with a favourable overall survival (OS) in HNSCC [p=0.037, hazard ratio (HR)=0.72, 95% confidence interval (CI)=0.53-0.98]. Furthermore, MB expression negatively correlated with human papillomavirus (HPV) status (p=0.013).

CONCLUSION: MB is differentially expressed in HNSCC and correlates with a better OS.

DOI10.21873/anticanres.11217
Alternate JournalAnticancer Res
PubMed ID27919941

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021